Mogamulizumab Biosimilar, Anti-human CCR4 Monoclonal Antibody | C053P

Catalog No.	C053P
Product Name	Mogamulizumab Biosimilar, Anti-human CCR4 Monoclonal Antibody | C053P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	CC chemokine receptor type 4, CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099, K5-5, C-C motif chemokine receptor 4
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Source/Host	The anti-human CC chemokine receptor 4 (CCR4) monoclonal antibody mogamulizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade mogamulizumab biosimilar specifically binds to the human CC chemokine receptor 4 (CCR4).
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by mogamulizumab.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade mogamulizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Mogamulizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C053P: Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab.

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions.

Mogamulizumab is derived from Kyowa Hakko Kirin’s POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.

Please remember our product information: Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody: C053P Syd Labs

No more offers for this product!